去甲丙咪嗪羟化表型的检测。 - Suppr | 超能文献

Detection of debrisoquine hydroxylation phenotypes.

作者信息

Wolf C R, Moss J E, Miles J S, Gough A C, Spurr N K

出版信息

Lancet. 1990 Dec 8;336(8728):1452-3. doi: 10.1016/0140-6736(90)93163-j.

DOI:10.1016/0140-6736(90)93163-j

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Detection of debrisoquine hydroxylation phenotypes.去甲丙咪嗪羟化表型的检测。

Lancet. 1990 Dec 8;336(8728):1452-3. doi: 10.1016/0140-6736(90)93163-j.

2

Genetic polymorphism of debrisoquine oxidation: restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6.异喹胍氧化的基因多态性：CYP2D6突变等位基因的限制性片段分析和等位基因特异性扩增

Methods Enzymol. 1991;206:173-83. doi: 10.1016/0076-6879(91)06088-k.

3

Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.膀胱黏膜和肿瘤组织中CYP2D6 mRNA多态性表达与体内异喹胍羟化酶活性的相关性。

Carcinogenesis. 1994 Sep;15(9):1955-61. doi: 10.1093/carcin/15.9.1955.

4

Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.异喹胍氧化多态性：CYP2D6基因第5外显子3个碱基对缺失的表型后果。

Pharmacogenetics. 1993 Jun;3(3):123-30.

5

Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.用于确定异喹胍4-羟化（细胞色素P4502D6）表型的遗传和代谢标准。

Pharmacogenetics. 1991 Oct;1(1):33-41. doi: 10.1097/00008571-199110000-00006.

6

NcoI RFLP in the pseudogene (CYP2D8P) of the human debrisoquine 4-hydroxylase locus.人异喹胍4-羟化酶基因座假基因（CYP2D8P）中的NcoI限制性片段长度多态性

Nucleic Acids Res. 1991 Mar 11;19(5):1162. doi: 10.1093/nar/19.5.1162.

7

Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.对与异喹胍/司巴丁遗传多态性相关的CYP2D6(A)和CYP2D6(B)无效等位基因的简单聚合酶链反应分析解读

Pharmacogenetics. 1994 Jun;4(3):154-8. doi: 10.1097/00008571-199406000-00006.

8

A BamHI polymorphism in the human cytochrome P450 gene, CYP2D6.人类细胞色素P450基因CYP2D6中的BamHI多态性。

Clin Genet. 1995 Feb;47(2):103-4. doi: 10.1111/j.1399-0004.1995.tb03934.x.

9

Mutant debrisoquine hydroxylation genes in Parkinson's disease.

Lancet. 1992 Apr 25;339(8800):1017-8. doi: 10.1016/0140-6736(92)90537-d.

10

Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease.家族性特发性帕金森病中的异喹胍羟基化基因型

Adv Neurol. 1996;69:97-100.

引用本文的文献

1

Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.白种人群体中CYP2D基因座XbaI定义的44kb等位基因的分子异质性。

Br J Clin Pharmacol. 1993 Feb;35(2):161-5. doi: 10.1111/j.1365-2125.1993.tb05681.x.

2

DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers.

Hum Genet. 1993 Oct;92(4):367-72. doi: 10.1007/BF01247337.

3

Polymerase chain reaction and its potential as a pharmacokinetic tool.聚合酶链反应及其作为药代动力学工具的潜力。

Clin Pharmacokinet. 1992 Nov;23(5):321-7. doi: 10.2165/00003088-199223050-00001.